Evidence map›Paper›PMID 38069305›Full record

ArticleInternational journal of molecular sciences2023

A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs.

Willy Smeralda, Marc Since, Sophie Corvaisier, Dimitri Fayolle, Julien Cardin, Sylvain Duprey, Jean-Pierre Jourdan, Christophe Cullin, Aurélie Malzert-Freon

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Willy SmeraldaNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.ORCID 0000-0001-6772-8993
Marc SinceNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.ORCID 0000-0003-3984-5812
Sophie CorvaisierNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.
Dimitri FayolleNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.ORCID 0000-0002-1543-136X
Julien CardinCIMAP, ENSICAEN, UNICAEN, UMR6252 CNRS, CEA, Normandie Université, 6 Bd du Maréchal Juin, 14050 Caen, France.ORCID 0000-0001-7069-4368
Sylvain DupreyCIMAP, ENSICAEN, UNICAEN, UMR6252 CNRS, CEA, Normandie Université, 6 Bd du Maréchal Juin, 14050 Caen, France.
Jean-Pierre JourdanNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.
Christophe CullinCBMN, CNRS UMR 5248, Université de Bordeaux, 33600 Pessac, France.
Aurélie Malzert-FreonNormandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.ORCID 0000-0001-6023-1861
Normandie Université · FRCentre National de la Recherche Scientifique · FR

Funding

French Ministry of Scientific Research and Innovation Doctoral fellowshipthe Region Normandie and the European Union via the European Regional Development Fund (FEDER). equipment funds
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most widespread form of senile dementia worldwide and represents a leading socioeconomic problem in healthcare. Although it is widely debated, the aggregation of the amyloid β peptide (Aβ) is linked to the onset and progression of this neurodegenerative disease. Molecules capable of interfering with specific steps in the fibrillation process remain of pharmacological interest. To identify such compounds, we have set up a small molecule screening process combining multiple experimental methods (UV and florescence spectrometry, ITC, and ATR-FTIR) to identify and characterise potential modulators of Aβ

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesAmyloidAmyloid beta-PeptidesBiomimeticsHumansAmyloidAmyloid beta-PeptidesAlzheimer’s diseasebexaroteneChicago sky bluedrug discoveryindomethacinliposomesβ-amyloïd

Identifiers

PMID38069305
PMCPMC10707238
OpenAlexW4389194681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.